Nov 16, 2022 / 01:00PM GMT
Paul Stone - IDEAYA Biosciences, Inc. - SVP & CFO
Yes, Ben, thanks for having us, and thanks to Stifel, for hosting us at the conference.
Ben Burnett - Stifel Financial Corp. - Analyst
To start off, maybe just give a brief overview of IDEAYA, and maybe talk about your approach with synthetic lethality, just highlight near-term events that we should be paying attention to.
Paul Stone - IDEAYA Biosciences, Inc. - SVP & CFO
Yes, IDEAYA is a precision medicine oncology company with a research and development focus in synthetic lethality. Our approach to synthetic lethality is straightforward. We are focused on identifying, then executing on targets that have the potential to be first-in-class. And we think therefore the most potentially impactful for patients.
We have currently two programs that are in clinical trials, our Phase 2 Darovasertib and our early Phase 2 IDE397 targeting MAT2A. But as we look forward over the next few quarters, we will have four programs in the clinic is what we're guiding
IDEAYA Biosciences Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers